Sugi Predict

Sugi Predict / Compounds / SCHEMBL2946799

SCHEMBL2946799

SCHEMBL2946799

COc1ccc2ncc(F)c(Br)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ GRM1 Q13255 1/20 0.42
▸ EGFR P00533 4/20 0.42
▸ GABRA1 P14867 1/20 0.42
▸ GABRG2 P18507 1/20 0.42
▸ GABRB3 P28472 1/20 0.42
▸ GABRA5 P31644 1/20 0.42
▸ GABRA3 P34903 1/20 0.42
▸ GABRA2 P47869 1/20 0.42
▸ HTR1A P08908 1/20 0.41
▸ ADRA1D P25100 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ ADRA1B P35368 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ F2 P00734 1/20 0.40
▸ GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5310728 0.88 KDM4E (0.37) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL2998324 0.81 SRC (0.45) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL29923658 0.81 SRC (0.45) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL5706839 0.81 CYP17A1 (0.44) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL29393432 0.81 KDM4E (0.46) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL2949117 0.81 KDM4E (0.46) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL4854355 0.81 LMNA (0.43) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL2535928 0.80 KCNH2 (0.43) LMNAKDM4EMAPTGRM1GABRA1
SCHEMBL2954867 0.77 KDM4E (0.42) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL5813519 0.77 KCNH2 (0.43) LMNAKDM4EMAPTGRM1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1695964-A1 Quinoline derivatives for use as intermediates in the synthesis of heterocyclylalcoyl piperidines NOVEXEL (FR) 2006-08-30 — — EP claimed
US-6903217-B2 Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them AVENTIS PHARMA S.A. (FR) 2005-06-07 — — US claimed
US-20140243302-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME CORPORATION (US) 2014-08-28 — — US disclosed
EP-2723737-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS Kyorin Pharmaceutical Co., Ltd. (JP) 2014-04-30 — — EP disclosed
WO-2013003383-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS KYORIN PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed
US-7759340-B2 Antibacterial agents GLAXO GROUP LIMITED (GB) 2010-07-20 — — US disclosed
US-7691850-B2 Antibacterial agents GLAXO GROUP LIMITED (GB) 2010-04-06 — — US disclosed
EP-1796466-A4 ANTIBACTERIAL AGENTS GLAXO GROUP LTD (GB) 2009-09-02 — — EP disclosed
US-20090181955-A1 Antibacterial Agents MILLER WILLIAM HENRY 2009-07-16 — — US disclosed
US-7511035-B2 Antibacterial agents GLAXO GROUP LIMITED (GB) 2009-03-31 — — US disclosed
US-20080139539-A1 Antibacterial Agents GLAXO GROUP LIMITED (GB) 2008-06-12 — — US disclosed
WO-2006014580-A1 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2006-02-09 — — WO disclosed
WO-2006002047-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2006-01-05 — — WO disclosed
US-6903217-B2 Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them AVENTIS PHARMA S.A. (FR) 2005-06-07 — — US disclosed
US-20040147518-A1 Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them AVENTIS PHARMA S.A. 2004-07-29 — — US disclosed
CN-1483031-A Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them ���ĵ�˹ҩ��ɷ����޹�˾ 2004-03-17 — — CN disclosed
EP-1337529-A2 HETEROCYCLYLALKYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2003-08-27 — — EP disclosed
US-6603005-B2 Bactericides AVENTIS PHARMA S.A. (FR) 2003-08-05 — — US disclosed
US-20020111492-A1 Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them NOVEXEL (FR) 2002-08-15 — — US disclosed
WO-2002040474-A2 HETEROCYCLYLALKYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIMICROBIAL AGENTS AVENTIS PHARMA S.A. (FR) 2002-05-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147518-A1 Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them SYNJ1, NCAPD2, SYNJ2 LMNA 295/4885KDM4E 4252/4885MAPT 1162/4885
US-20020111492-A1 Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them SYNJ1, NCAPD2, SYNJ2 LMNA 295/4885KDM4E 4252/4885MAPT 1162/4885
US-20080139539-A1 Antibacterial Agents NQO2, NQO1, NRDC LMNA 2827/4885KDM4E 4536/4885MAPT 4569/4885
US-20090181955-A1 Antibacterial Agents NQO2, NQO1, NRDC LMNA 2827/4885KDM4E 4536/4885MAPT 4569/4885
US-20140243302-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS PAICS, SBDS, SORD LMNA 2982/4885KDM4E 4131/4885MAPT 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.